P/B
1,3
CorMedix
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
$581.5M
Market Cap • 10/15/2026
2006
(20 years)
Founded
2010
(16 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
1,3
P/EBITDA
2,3
P/OCF
2,3
P/FCF
2,3
P/E
3,5
BVPS
5,9
EPS
2
Market Cap
Market Cap
581,5M
EV
469,9M
EV/Revenue
1
EV/EBITDA
1,9
EV/EBIT
2,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-12%
Total Yield
-12%
Payout
0%
Retained Earnings
-112M
Profitability
Gross Margin
82,8%
EBITDA Margin
54,8%
EBIT Margin
47%
Net Margin
40,5%
D&A/EBITDA
0%
R&D/Revenue
-8,4%
Capex/Revenue
0,8%
Capex/D&A
9,6%
Capex/OCF
1,4%
SBC/OCF
6,4%
% PPE
0,9%
% Goodwill
3,3%
ROE
54,9%
ROIC
88,5%
Growth
CAGR Revenue 5Y
351,9%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
2,6
Quick Ratio
2,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!